Generic Paxil Maker Plans Follow Up To $107 Million Verdict Against Glaxo

, New Jersey Law Journal

   | 0 Comments

Mylan Pharmaceuticals hopes its $107 million verdict against GlaxoSmithKline is just the first of a two-part victory in preserving its rights to market generic Paxil.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202648999067

Thank you!

This article's comments will be reviewed.